| Baricitinib | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Baricitinib | hsa00280 | Valine, leucine and isoleucine degradation | 3.41E-03 | 4 | P55809, Q9HCC0, Q02252, P11310 | OXCT1, MCCC2, ALDH6A1, ACADM | More | |
| Baricitinib | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Baricitinib | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Baricitinib | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Baricitinib | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.27E-05 | 2 | P40925, P15104 | MDH1, GLUL | More | |
| Baricitinib | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Baricitinib | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Baricitinib | hsa01522 | Endocrine resistance | 4.74E-02 | 3 | P22694, P10415, Q13323 | PRKACB, BCL2, BIK | More | |
| Baricitinib | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
| Baricitinib | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | |
| Baricitinib | hsa03013 | RNA transport | 4.13E-02 | 6 | Q09161, P35658, P47813, Q14152, O75822, P51114 | NCBP1, NUP214, EIF1AX, EIF3A, EIF3J, FXR1 | More | |
| Baricitinib | hsa03020 | RNA polymerase | 2.61E-03 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | |
| Baricitinib | hsa03040 | Spliceosome | 8.73E-04 | 8 | Q14562, O43143, O60508, P08579, Q07955, Q01130, Q13243, O43447 | DHX8, DHX15, CDC40, SNRPB2, SFRS1, SFRS2, SFRS5, PPIH | More | |
| Baricitinib | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | |
| Baricitinib | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | |
| Baricitinib | hsa04024 | cAMP signaling pathway | 4.38E-02 | 4 | P42338, P0DP23, Q13370, Q13009 | PIK3CB, CALM1, PDE3B, TIAM1 | More | |
| Baricitinib | hsa04064 | NF-kappa B signaling pathway | 2.35E-02 | 4 | P01584, P63279, Q8NHW4, Q9NQC7 | IL1B, UBE2I, CCL4L2, CYLD | More | |
| Baricitinib | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | |
| Baricitinib | hsa04080 | Neuroactive ligand-receptor interaction | 4.90E-03 | 6 | P08311, Q15722, P21453, Q9H228, O00398, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, ADRB2 | More | |
| Baricitinib | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Baricitinib | hsa04140 | Autophagy - animal | 4.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | |
| Baricitinib | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | |
| Baricitinib | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | |
| Baricitinib | hsa04144 | Endocytosis | 1.67E-02 | 8 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, GIT2, SNX12 | More | |
| Baricitinib | hsa04213 | Longevity regulating pathway - multiple species | 2.82E-02 | 3 | Q08828, P51828, P0DMV8 | ADCY1, ADCY7, HSPA1A | More | |
| Baricitinib | hsa04217 | Necroptosis | 4.42E-04 | 6 | P07900, P15104, P05141, P01584, P0C0S5, Q13557 | HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D | More | |
| Baricitinib | hsa04270 | Vascular smooth muscle contraction | 6.96E-03 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | |
| Baricitinib | hsa04340 | Hedgehog signaling pathway | 9.74E-03 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | |
| Baricitinib | hsa04360 | Axon guidance | 1.71E-02 | 4 | P20827, O95631, P42338, P23528 | EFNA1, NTN1, PIK3CB, CFL1 | More | |
| Baricitinib | hsa04370 | VEGF signaling pathway | 3.06E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Baricitinib | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Baricitinib | hsa04540 | Gap junction | 2.86E-02 | 3 | P22694, P68371, Q14643 | PRKACB, TUBB2C, ITPR1 | More | |
| Baricitinib | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.73E-02 | 3 | Q13873, Q02750, Q86SE9 | BMPR2, MAP2K1, PCGF5 | More | |
| Baricitinib | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Baricitinib | hsa04613 | Neutrophil extracellular trap formation | 1.73E-02 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Baricitinib | hsa04623 | Cytosolic DNA-sensing pathway | 1.65E-02 | 2 | P01584, Q8NHW4 | IL1B, CCL4L2 | More | |
| Baricitinib | hsa04650 | Natural killer cell mediated cytotoxicity | 3.73E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | |
| Baricitinib | hsa04657 | IL-17 signaling pathway | 4.87E-02 | 2 | P07900, P01584 | HSP90AA1, IL1B | More | |
| Baricitinib | hsa04659 | Th17 cell differentiation | 4.38E-02 | 4 | P42224, P14784, P40189, P08238 | STAT1, IL2RB, IL6ST, HSP90AB1 | More | |
| Baricitinib | hsa04662 | B cell receptor signaling pathway | 1.49E-03 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | |
| Baricitinib | hsa04664 | Fc epsilon RI signaling pathway | 2.32E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | |
| Baricitinib | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | |
| Baricitinib | hsa04720 | Long-term potentiation | 2.85E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Baricitinib | hsa04724 | Glutamatergic synapse | 5.94E-03 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | |
| Baricitinib | hsa04725 | Cholinergic synapse | 3.62E-03 | 6 | P22694, Q14643, P63218, P50151, P42338, P10415 | PRKACB, ITPR1, GNG5, GNG10, PIK3CB, BCL2 | More | |
| Baricitinib | hsa04727 | GABAergic synapse | 1.63E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
| Baricitinib | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.01E-02 | 4 | P01584, Q08828, P51828, P0DP23 | IL1B, ADCY1, ADCY7, CALM1 | More | |
| Baricitinib | hsa04913 | Ovarian steroidogenesis | 2.72E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Baricitinib | hsa04914 | Progesterone-mediated oocyte maturation | 9.70E-04 | 7 | Q17RY0, P42338, Q13370, Q9Y6D9, P08238, P51812, Q02750 | CPEB4, PIK3CB, PDE3B, MAD1L1, HSP90AB1, RPS6KA3, MAP2K1 | More | |
| Baricitinib | hsa04915 | Estrogen signaling pathway | 3.17E-02 | 5 | Q08828, P51828, P0DMV8, P0DP23, Q15788 | ADCY1, ADCY7, HSPA1A, CALM1, NCOA1 | More | |
| Baricitinib | hsa04924 | Renin secretion | 2.65E-04 | 5 | P22694, P07550, Q14643, Q13370, P0DP23 | PRKACB, ADRB2, ITPR1, PDE3B, CALM1 | More | |
| Baricitinib | hsa04926 | Relaxin signaling pathway | 5.70E-03 | 5 | P42338, P63218, P50151, P49767, P49407 | PIK3CB, GNG5, GNG10, VEGFC, ARRB1 | More | |
| Baricitinib | hsa04927 | Cortisol synthesis and secretion | 2.72E-02 | 2 | Q14643, P22694 | ITPR1, PRKACB | More | |
| Baricitinib | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.02E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | |
| Baricitinib | hsa04929 | GnRH secretion | 4.62E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | |
| Baricitinib | hsa04932 | Non-alcoholic fatty liver disease | 5.01E-04 | 8 | O43521, P18848, O75460, P01584, P13073, P12074, O15239, O95298 | BCL2L11, ATF4, ERN1, IL1B, COX4I1, COX6A1, NDUFA1, NDUFC2 | More | |
| Baricitinib | hsa04934 | Cushing syndrome | 4.74E-02 | 3 | Q14643, P22694, P04628 | ITPR1, PRKACB, WNT1 | More | |
| Baricitinib | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Baricitinib | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Baricitinib | hsa04970 | Salivary secretion | 2.62E-03 | 6 | P07550, Q08828, P51828, P22694, Q14643, P0DP23 | ADRB2, ADCY1, ADCY7, PRKACB, ITPR1, CALM1 | More | |
| Baricitinib | hsa04976 | Bile secretion | 4.78E-02 | 3 | Q08828, P51828, Q14032 | ADCY1, ADCY7, BAAT | More | |
| Baricitinib | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | |
| Baricitinib | hsa05016 | Huntington disease | 2.72E-03 | 11 | O15239, O95298, P13073, P12074, P24928, P30876, P62487, P05141, O75460, P28070, O00232 | NDUFA1, NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4, PSMD12 | More | |
| Baricitinib | hsa05020 | Prion disease | 3.37E-03 | 7 | P13591, P01584, P11142, O15239, P13073, P18848, P05141 | NCAM1, IL1B, HSPA8, NDUFA1, COX4I1, ATF4, SLC25A5 | More | |
| Baricitinib | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.80E-02 | 6 | O15239, P13073, P18848, P05141, P01584, Q13557 | NDUFA1, COX4I1, ATF4, SLC25A5, IL1B, CAMK2D | More | |
| Baricitinib | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Baricitinib | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | |
| Baricitinib | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Baricitinib | hsa05134 | Legionellosis | 1.18E-03 | 5 | P01584, Q9NR31, P68104, P0DMV8, P11142 | IL1B, SAR1A, EEF1A1, HSPA1A, HSPA8 | More | |
| Baricitinib | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | |
| Baricitinib | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
| Baricitinib | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
| Baricitinib | hsa05150 | Staphylococcus aureus infection | 2.44E-02 | 4 | P21462, Q14532, P59665, P59666 | FPR1, KRT32, DEFA1; DEFA1B, DEFA3 | More | |
| Baricitinib | hsa05162 | Measles | 3.74E-03 | 5 | P23458, P0DMV8, P11142, P01584, Q9NP90 | JAK1, HSPA1A, HSPA8, IL1B, RAB9B | More | |
| Baricitinib | hsa05163 | Human cytomegalovirus infection | 3.31E-02 | 7 | P0DP23, Q8NHW4, Q08828, P51828, P23458, P01584, Q13651 | CALM1, CCL4L2, ADCY1, ADCY7, JAK1, IL1B, IL10RA | More | |
| Baricitinib | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | |
| Baricitinib | hsa05169 | Epstein-Barr virus infection | 3.72E-02 | 6 | Q13547, P42338, P07948, Q13761, O75293, P07766 | HDAC1, PIK3CB, LYN, RUNX3, GADD45B, CD3E | More | |
| Baricitinib | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | |
| Baricitinib | hsa05200 | Pathways in cancer | 3.92E-02 | 9 | P42338, P08238, P42224, P43246, P14923, O75293, P0DP23, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, MSH2, JUP, GADD45B, CALM1, IL2RB, IL6ST | More | |
| Baricitinib | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
| Baricitinib | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Baricitinib | hsa05212 | Pancreatic cancer | 1.72E-02 | 3 | P42338, P42224, O75293 | PIK3CB, STAT1, GADD45B | More | |
| Baricitinib | hsa05214 | Glioma | 1.72E-02 | 3 | P0DP23, P42338, O75293 | CALM1, PIK3CB, GADD45B | More | |
| Baricitinib | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Baricitinib | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
| Baricitinib | hsa05415 | Diabetic cardiomyopathy | 2.87E-02 | 4 | P05141, O15239, P13073, Q13557 | SLC25A5, NDUFA1, COX4I1, CAMK2D | More | |
| Baricitinib | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | |
